MissionIR Articles
-
Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Advances Precision Therapeutics by Learning Cancer Behavior, Improving Outcomes
Predictive Oncology subsidiary TumorGenesis developing faster, less costly and more accurate PDx cancer models that better mimic patient’s tumor TumorGenesis revolutionary technology will provide pharmaceuticals with quicker, more effective drug development while significantly improving patient…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Names New Member to Board of Directors
Predictive Oncology (NASDAQ: POAI) recently announced the appointment of Pam Prior, CPA, to the company’s Board of Directors. In addition to holding a seat on the board, Prior will also chair the company’s audit committee.…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Launches Innovative Culture Media for Growing Ovarian Tumor Cells in the Lab
Predictive Oncology (NASDAQ: POAI), together with its subsidiary, TumorGenesis, Inc., today announced that it has selected US Biological Corporation of Salem, Massachusetts as the manufacturer and distributor of its innovative culture media for growing ovarian…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Leverages Unique Competitive Advantage
Predictive Oncology (NASDAQ: POAI), a data and artificial-intelligence- (“AI”) driven, discovery-services company, possesses a unique advantage over its competition in the form of samples and access to historical data on clinical outcomes. This data could…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Inks LOI to Acquire Quantitative Medicine
Predictive Oncology (NASDAQ: POAI), a data and artificial-intelligence- (“AI”) driven, discovery-services company, today announced that it has signed a letter of intent (“LOI”) to acquire Quantitative Medicine (“QM”), a biomedical analytics and computational biology company.…
-
Predictive Oncology Inc. (NASDAQ: POAI) Appoints New Board Member, Audit Committee Chair
New board member, audit committee chair brings 35 years of accounting experience, mainly in management Prior worked as CFO, controller in several genomics, health companies POAI to leverage Prior’s new insights, guidance in the financial…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Aims to Commercialize AI-Driven Predictive Model of Ovarian Cancer in Q1 2020
Predictive Oncology (NASDAQ: POAI), a data and artificial-intelligence- (“AI”) driven, discovery-services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, recently issued an update regarding its groundbreaking CancerQuest 2020…
-
Predictive Oncology Inc. (NASDAQ: POAI), Leader in Precision Medicine, Committed to Playing Key Role in Decreasing Cancer Deaths
American Cancer Society annual report shows largest single-year drop in cancer deaths ever reported Doctors attribute precision medicine with playing significant role in decline POAI leading player in precision medicine, initiated groundbreaking Cancer Quest 2020…
-
Predictive Oncology Inc.’s (NASDAQ: POAI) Disruptive Platform Overcoming Obstacles in Precision Medicine Industry
The global precision medicine market is estimated to reach $84.6 billion by 2024 Predictive Oncology is bringing cutting-edge technology to cancer research to develop highly customizable assessment methods that improve patient outcomes POAI leverages unique…
-
Predictive Oncology Inc. (NASDAQ: POAI) Working to Create World’s First Comprehensive, Actionable Multi-Omic Data Set for Ovarian Cancer
POAI plans to have first predictive model of ovarian cancer ready for initial commercialization in Q1 2020 First batch of 400 ovarian cancer subjects in initiative has been sequenced Groundbreaking AI-driven model of ovarian cancer…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Appointment of Pam Prior to its Board of Directors
Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced the unanimous appointment of Pam…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Building AI-driven Ovarian Cancer Model to Predict Tumor Drug Response, Patient Outcome
Predictive Oncology (NASDAQ: POAI), through its subsidiary Helomics, is sequencing ovarian cancers as part of a CancerQuest 2020 project, building the largest ovarian multi-omic database in the world. An article discussing the company reads, “As…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary’s Revolutionary Technology Enables Faster, More Accurate Tumor Identification
Data and artificial-intelligence (“AI”) driven, discovery-services company Predictive Oncology’s (NASDAQ: POAI) subsidiary TumorGenesis is developing quicker, less costly and more precise Patient Derived Xenograft (“PDx”) cancer models that better mimic the patient’s tumor. An article…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Extension of Secured Promissory Note
Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced the extension of its secured…
-
Predictive Oncology Inc. (NASDAQ: POAI) Notes Indications of Interest in Medical Division; Regains Nasdaq Price Compliance
Several parties have indicated interest in potential acquisition of POAI’s Skyline Medical division The division has seen recent success with growing sales of its patented, FDA-approved STREAMWAY System POAI also regained compliance with Nasdaq’s minimum…
-
Predictive Oncology Inc. (NASDAQ: POAI) Reports 58% Revenue Increase; Notes Business Highlights for Q3 2019
POAI sees Q3 2019 revenue total $522,696 from $329,930 in Q3 2018 Company reports records sales of proprietary systems, supplies Significant business highlights indicate continued momentum as Predictive Oncology looks to bright future Predictive Oncology…
-
Predictive Oncology Inc. (NASDAQ: POAI) Key Player in AI Implementation in Ovarian Cancer Detection
POAI subsidiary sequencing ovarian cancers as part of CancerQuest 2020 project, building largest ovarian multi-omic database in the world Company’s work designed to speed development of new drugs, provide therapeutic choices Helomics recently signed collaborative…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Updates on Commercialization of Cancer Quest 2020 Initiative
Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced updates on the commercialization of…
-
Predictive Oncology Inc.’s (NASDAQ: POAI) TumorGenesis Tech Primed to Play Key Role in Cancer Drug Development Efforts
Predictive Oncology subsidiary TumorGenesis developing faster, less costly, and more accurate PDx cancer models that better mimic the patient’s tumor TumorGenesis revolutionary technology will provide pharmaceuticals with quicker and more effective drug development while significantly…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Multiple Indications of Interest for Skyline Medical Division
Predictive Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its receipt of interest from several parties for the possible acquisition of its Skyline Medical division, which…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Marks Pivotal Moment on Path to 2026 Rare Earth Oxide Production
- PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) Marks Bold Entry Into the Growing Battery Storage Market with 4.99 MW BESS in Ontario
- Soligenix Inc. (NASDAQ: SNGX) Working to Advance Heat-Stable Ricin Vaccine with Promising Efficacy
- New Pacific Metals Corp. (NYSE American: NEWP) (TSX: NUAG) Eyes Bolivia’s Untapped Silver Potential Amid Global Supply Gaps
- MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q2 2025 Results, Advances TPI 287 Toward Phase 2 GBM Trial